PL437870A1 - Sposób wykrywania raka prostaty o złym rokowaniu - Google Patents

Sposób wykrywania raka prostaty o złym rokowaniu

Info

Publication number
PL437870A1
PL437870A1 PL437870A PL43787021A PL437870A1 PL 437870 A1 PL437870 A1 PL 437870A1 PL 437870 A PL437870 A PL 437870A PL 43787021 A PL43787021 A PL 43787021A PL 437870 A1 PL437870 A1 PL 437870A1
Authority
PL
Poland
Prior art keywords
prostate cancer
poor prognosis
detecting poor
detecting
prognosis prostate
Prior art date
Application number
PL437870A
Other languages
English (en)
Other versions
PL244067B1 (pl
Inventor
Cezary Cybulski
Original Assignee
Cezary Cybulski
Pomorski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cezary Cybulski, Pomorski Uniwersytet Medyczny filed Critical Cezary Cybulski
Priority to PL437870A priority Critical patent/PL244067B1/pl
Publication of PL437870A1 publication Critical patent/PL437870A1/pl
Publication of PL244067B1 publication Critical patent/PL244067B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób oceny czy w materiale biologicznym badanej osoby występuje specyficzna zmiana konstytucyjna w genie PALB2. Wynalazek dotyczy nowej metody diagnostycznej wykrywającej genetyczną predyspozycję do agresywnego raka prostaty o złym rokowaniu co do przeżycia.
PL437870A 2021-05-16 2021-05-16 Sposób wykrywania raka prostaty o złym rokowaniu PL244067B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL437870A PL244067B1 (pl) 2021-05-16 2021-05-16 Sposób wykrywania raka prostaty o złym rokowaniu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437870A PL244067B1 (pl) 2021-05-16 2021-05-16 Sposób wykrywania raka prostaty o złym rokowaniu

Publications (2)

Publication Number Publication Date
PL437870A1 true PL437870A1 (pl) 2022-11-21
PL244067B1 PL244067B1 (pl) 2023-11-27

Family

ID=84191821

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437870A PL244067B1 (pl) 2021-05-16 2021-05-16 Sposób wykrywania raka prostaty o złym rokowaniu

Country Status (1)

Country Link
PL (1) PL244067B1 (pl)

Also Published As

Publication number Publication date
PL244067B1 (pl) 2023-11-27

Similar Documents

Publication Publication Date Title
Swords et al. Biomarkers in pancreatic adenocarcinoma: current perspectives
Wang et al. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer
Makridakis et al. Secretome proteomics for discovery of cancer biomarkers
Ferris et al. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile–based classification
Larkin et al. Identification of markers of prostate cancer progression using candidate gene expression
Long et al. Matrix metalloproteinase-7 mRNA and protein expression in gastric carcinoma: a meta-analysis
Yerushalmi et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
Sheng et al. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer
Chen et al. External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort
Dai et al. Transcriptome profiling reveals an integrated mRNA–lncRNA signature with predictive value of early relapse in colon cancer
Hsueh et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma
Pan et al. m5C-related lncRNAs predict overall survival of patients and regulate the tumor immune microenvironment in lung adenocarcinoma
Ajili et al. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34
Shi et al. Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles
Egger et al. Diversity of stage III melanoma in the era of sentinel lymph node biopsy
Gaughran et al. The utility of the tumor markers CA15. 3, CEA, CA-125 and CA19. 9 in metastatic breast cancer
Chan et al. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for “large” cribriform prostatic adenocarcinoma
Liu et al. Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer
Yu et al. Identification of N6-methyladenosine-associated long non-coding RNAs for immunotherapeutic response and prognosis in patients with pancreatic cancer
Andreopoulou et al. Circulating tumor cells as prognostic marker in metastatic breast cancer
Szarvas et al. Urinary protein markers for the detection and prognostication of urothelial carcinoma
Saling et al. Wnt5a/planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker
Su et al. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma
Murphy et al. Patented prostate cancer biomarkers
Chen et al. The diagnostic value of survivin in malignant pleural effusion: A meta-analysis